Conditions: Cardiovascular Disease

Intervention Type: Drug

Intervention Name: Placebo

Clinical Trials

The following are clinical trials from the Healia Clinical Trials Information Database that are researching the effect of the "Drug" intervention "Placebo" on "Cardiovascular Disease".

• Effects of High Dose Simvastatin Therapy on Glucose Metabolism and Ectopic Lipid Deposition in Non-Obese Type 2 Diabetic Patients

  NCTID: NCT00704314

• Is Spironolactone Safe and Effective in the Treatment of Cardiovascular Disease in Mild Chronic Renal Failure?

  NCTID: NCT00291720

• Effect of Raltegravir on Endothelial Function in HIV-Infected Patients

  NCTID: NCT00843713

• HDL Increased Plaque Stabilization in the Elderly

  NCTID: NCT00127218

• Salsalate Therapy to Reduce Insulin Resistance and Cardiovascular Risk

  NCTID: NCT00330733

• SEARCH: Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine

  NCTID: NCT00124072

• Feasibility of Omega-3 Fatty Acid Supplementation in Adult Hemodialysis Patients

  NCTID: NCT01002118

• ROS Signaling in Endothelial Function

  NCTID: NCT01037465

• Role of Vitamin D in Secondary Prevention of Cardiovascular Events

  NCTID: NCT01018849

• The Metformin in CABG (MetCAB) Trial

  NCTID: NCT01438723

• Phase 3 Randomized Trial of Tadalafil and Glycemic Traits

  NCTID: NCT01444651

• Vitamin D, Insulin Resistance, and Cardiovascular Disease

  NCTID: NCT00736632

• LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)

  NCTID: NCT00799903

• A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE).

  NCTID: NCT01000727

• A 24-week, Multicentre, Randomised, Double-blind,Age-stratified, Placebo Controlled Phase III Study With an 80-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin 10 mg /Day in Patients With T2DM and Cardiovascular Disease, Who Exhibit Inadequate Glycaemic Control on Usual Care

  NCTID: NCT01042977

• The Effect of Dulaglutide on Major Cardiovascular Events in Patients With Type 2 Diabetes: Researching Cardiovascular Events With a Weekly INcretin in Diabetes (REWIND)

  NCTID: NCT01394952

• A Double Blind, Randomized, Placebo Controlled Study to Determine the Physiological Effectiveness of Januvia (100 mg/d) for Reducing Inflammation and Increasing Endothelial Progenitor Cell Number in Human Immunodeficiency Virus (HIV) Infected Men and Women With Insulin Resistance and Central Adiposity.

  NCTID: NCT01552694

• A Multi-Center, Double-blind, Randomized, Placebo Controlled, Parallel Group Study of the Effect of Dalcetrapib on Atherosclerotic Disease Progression As Measured by Coronary Intravascular Ultrasound, Carotid B-Mode Ultrasound and Coronary Angiography

  NCTID: NCT01059682

• A 24-week, Multicentre, Randomised, Double-blind, Age-stratified, Placebo Controlled, Phase III Study With a 80-week Extension Period to Evaluate the Efficacy and Safety of Dapagliflozin 10 mg/Day in Pts With T2DM, CV Disease and Hypertension Who Exhibit Inadequate Glycaemic Control on Usual Care

  NCTID: NCT01031680

• Statin Therapy to Improve Inflammation and Atherosclerosis in HIV Patients

  NCTID: NCT00965185

• A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbepoetin Alfa Treatment on Mortality and Morbidity in Heart Failure (HF) Subjects With Symptomatic Left Ventricular Systolic Dysfunction and Anemia

  NCTID: NCT00358215

• A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Determine Whether, in Patients With Type 2 Diabetes at High Risk for Cardiovascular and Renal Events, Aliskiren, on Top of Conventional Treatment, Reduces Cardiovascular and Renal Morbidity and Mortality

  NCTID: NCT00549757

---